Incytevs.United Therapeutics
INCY vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Incyte and United Therapeutics are similar in size by market cap; Incyte trades at the lower P/E (15.1 vs 17.0); year to date, Incyte leads (+29.6% vs +5.3%).
Side by side
| INCY | UTHR | |
|---|---|---|
| Market cap | $24.4B | $22.3B |
| Price | $129.72 | $518.53 |
| Today | +1.4% | +1.1% |
| Return YTD | +29.6% | +5.3% |
| Return 1Y | +50.5% | +64.3% |
| P/E | 15.1 | 17.0 |
| P/S | 4.2 | 7.1 |
| P/B | 3.8 | 3.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More INCY & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.
See where INCY and UTHR sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →